Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NSAID gastrointestinal toxicity.

B Cryer1

  • 1Medical Service, Department of Veterans Affairs Medical Center and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75216, USA. bcryer@mednet.swmed.edu

Current Opinion in Gastroenterology
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.

Current medical research and opinion·2010
Same author

Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.

Alimentary pharmacology & therapeutics·2010
Same author

Nonsteroidal anti-inflammatory drug gastrointestinal toxicity.

Current opinion in gastroenterology·2006
Same author

Nonsteroidal anti-inflammatory drug gastrointestinal toxicity.

Current opinion in gastroenterology·2006
Same author

Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.

Alimentary pharmacology & therapeutics·2006
Same author

Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.

Alimentary pharmacology & therapeutics·2005
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Nonsteroidal anti-inflammatory drugs (NSAIDs) commonly cause gastrointestinal ulcers. Recent research has advanced understanding of NSAID toxicity, identified at-risk patients, and developed safer NSAID alternatives.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Internal Medicine

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
  • Upper gastrointestinal ulcers are the most common adverse effects of NSAID use.
  • NSAID-induced gastrointestinal toxicity remains a significant clinical challenge.

Purpose of the Study:

  • To review recent advances in understanding and mitigating NSAID-induced gastrointestinal toxicity.
  • To highlight new developments in NSAID safety and risk management.
  • To provide an overview of improved NSAID safety profiles.

Main Methods:

  • Literature review of recent laboratory and clinical studies.
  • Analysis of advancements in NSAID gastrointestinal safety.

Related Experiment Videos

  • Synthesis of findings on NSAID toxicity mechanisms and risk factors.

    • Main Results:

    • Delineation of mechanisms underlying NSAID-induced gastrointestinal toxicity.
    • Identification of patient populations at higher risk for NSAID complications.
    • Development of NSAID classes with improved gastrointestinal safety profiles.
    • Recognition of co-therapies that can reduce NSAID toxicity.

    Conclusions:

    • Significant progress has been made in reducing NSAID gastrointestinal toxicity.
    • Recent research has enhanced the understanding of NSAID-related risks.
    • Newer NSAID formulations and therapeutic strategies offer improved gastrointestinal safety.